Arizona SB1542 amends laws regarding controlled substances, specifically midomafetamine, and establishes conditions for its approval and use in.
Arizona SB1542 amends the state's controlled substances laws to include midomafetamine, pending its approval by the FDA and scheduling by the DEA. It mandates the Arizona Industrial Commission to assign reimbursement values for midomafetamine and publish billing guidelines upon meeting certain conditions. The bill also requires the Arizona State Board of Pharmacy to notify the Arizona Legislative Council if the conditions for midomafetamine's approval are met.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.